within Pharmacolibrary.Drugs.ATC.D;

model D11AH12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.54,
    Cl             = 0.00265,
    adminDuration  = 600,
    adminMass      = 0.06,
    adminCount     = 1,
    Vd             = 0.0057,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00025,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Nemolizumab is a humanized monoclonal antibody that targets interleukin-31 receptor A (IL-31RA), inhibiting the action of IL-31, a cytokine involved in the pathogenesis of pruritus and atopic dermatitis. It is primarily investigated and used for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis, particularly in patients with insufficient response to topical therapies. As of early 2024, nemolizumab is approved for medical use in Japan for pruritus associated with atopic dermatitis and is under regulatory review or in late-stage clinical trials in other regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for adult patients with moderate-to-severe atopic dermatitis receiving subcutaneous administration.</p><h4>References</h4><ol><li><p>Sidbury, R, et al., &amp; Piketty, C (2022). Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents. <i>Dermatology and therapy</i> 12(3) 631–642. DOI:<a href=&quot;https://doi.org/10.1007/s13555-021-00678-7&quot;>10.1007/s13555-021-00678-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35088348/&quot;>https://pubmed.ncbi.nlm.nih.gov/35088348</a></p></li><li><p>Wagner, N, et al., &amp; Piketty, C (2023). Selection of Nemolizumab Clinical Dosage for Atopic Dermatitis. <i>Journal of drugs in dermatology : JDD</i> 22(10) 1017–1020. DOI:<a href=&quot;https://doi.org/10.36849/JDD.7437R1&quot;>10.36849/JDD.7437R1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37801534/&quot;>https://pubmed.ncbi.nlm.nih.gov/37801534</a></p></li><li><p>Kaneda, N (2023). [Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis]. <i>Nihon yakurigaku zasshi. Folia pharmacologica Japonica</i> 158(3) 282–289. DOI:<a href=&quot;https://doi.org/10.1254/fpj.22150&quot;>10.1254/fpj.22150</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37121713/&quot;>https://pubmed.ncbi.nlm.nih.gov/37121713</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D11AH12;
